OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

Currentblue cross blue shield - south dakotaPolicy N/A

Esophageal pH Monitoring

Customize your policy alerts

Sign up for all blue cross blue shield - south dakota policy alerts

Know when blue cross blue shield - south dakota releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs the medical necessity and coverage of catheter-based, wireless, and impedance esophageal pH monitoring for evaluation of gastroesophageal reflux disease (GERD) in adults, children, and adolescents, including indications for surgical candidacy and specific pediatric indications.

Policy Summary

Payerblue cross blue shield - south dakota

PolicyEsophageal pH Monitoring

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateSep 1, 2004

Last ReviewNov 1, 2025

Next Review DateN/A

Key ActionDocument prior evaluations and PPI status and ensure testing meets the policy's medical necessity criteria before requesting esophageal pH monitoring.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

24-96 htypical monitoring duration

select listedmedically necessary indications

insufficientevidence for net health outcome

0RCTs on clinical utility

96 hpreferred prolonged duration (guidelines)

Coverage and Medical Necessity Criteria

inv-01: Medically necessary indications

Covered when ANY of the following clinical indications are met

Adult/Adolescent indications: Esophageal pH monitoring (catheter or wireless) is medically necessary for: (1) documentation of abnormal acid exposure in endoscopy-negative individuals being considered for surgical antireflux repair; (2) evaluation of individuals after antireflux surgery who are suspected of having ongoing abnormal reflux; (3) evaluation of individuals with normal or equivocal endoscopic findings and reflux symptoms refractory to proton pump inhibitor (PPI) therapy; (4) evaluation of refractory reflux in individuals with chest pain after cardiac evaluation and after a 1-month trial of PPI therapy; (5) evaluation of suspected otolaryngologic manifestations of GERD (laryngitis, pharyngitis, chronic cough) in individuals who have failed to respond to at least 4 weeks of PPI therapy; (6) evaluation of concomitant GERD in individuals with adult-onset, nonallergic asthma suspected of having reflux-induced asthma.see node text

Applies to adults and children/adolescents able to report symptoms.

Pediatric indications (infants/children unable to report symptoms): Twenty-four-hour catheter-based esophageal pH monitoring is medically necessary for infants or children who are unable to report or describe symptoms with unexplained apnea, bradycardia, refractory coughing or wheezing/stridor/recurrent choking (aspiration), persistent or recurrent laryngitis, or recurrent pneumonia.

Policy Summary

Payerblue cross blue shield - south dakota

PolicyEsophageal pH Monitoring

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateSep 1, 2004

Last ReviewNov 1, 2025

Next Review DateN/A

Key ActionDocument prior evaluations and PPI status and ensure testing meets the policy's medical necessity criteria before requesting esophageal pH monitoring.

SourceLink

On This Page

Applies when child cannot report or describe symptoms.

inv-02: Investigational indications

Not covered / investigational

Investigational uses: Esophageal pH monitoring (catheter- or wireless-based system) not meeting the above specified criteria is considered investigational because the evidence is insufficient to determine effects on net health outcomes.N/A

Applies to uses outside the listed indications.

inv-03: Medical necessity criteria for pH monitoring

Covered when ALL of the following are met

Indication: Patient has suspected or known GERD and testing is being considered to inform treatment or management decisions.

Based on intended clinical populations for pH monitoring.

Prior medical therapy: Symptoms have not responded to an adequate program of medical therapy, including an appropriate trial of proton pump inhibitor therapy.

Catheter-based monitoring is primarily used after medical therapy failure (catheter-based context).

Test modality: Catheter-based or wireless pH monitoring may be used; wireless monitoring allows prolonged ambulatory recording and may increase diagnostic yield compared with 24-hour catheter testing.

Modality choice depends on clinical context and patient tolerance.

inv-04: Coverage considerations

Evidence-based considerations for use

General evidence-based conditions: Prolonged wireless pH monitoring or impedance-pH testing may be considered when results are likely to change management (for example, persistent symptoms despite a negative 24-hour catheter study or ongoing symptoms while on PPI therapy). However, clinical validity is limited by the absence of a reference standard and there are no randomized controlled trials demonstrating improved patient outcomes from these tests.

Supported by cohort studies showing increased diagnostic yield with longer monitoring and with impedance addition, but without demonstrated outcome benefit.

inv-05: Indications and diagnostic criteria from consensus/guidelines

Use of esophageal pH and impedance monitoring is supported by multiple society guidelines/consensus for specific diagnostic scenarios and to guide management:

Unproven GERD diagnosis off PPI: Perform prolonged wireless pH monitoring off antisecretory therapy (preferred 96 hours when available) to establish the diagnosis in patients with suspected GERD when endoscopy is nondiagnostic.acid exposure time >6% on 2 or more days diagnostic

Recommended by ACG, AGA, Lyon Consensus, and RAND appropriateness statements.

Refractory symptoms on PPI: Perform pH-impedance monitoring while on PPI therapy to evaluate persistent symptoms and to distinguish acid from nonacid reflux as a cause of symptoms.on-therapy acid exposure >4% and >80 reflux episodes/day suggest refractory disease

Supported by ACG and international consensus recommendations for on-therapy testing.

Patients intolerant of catheter: Use wireless pH monitoring for patients who cannot tolerate a transnasal catheter or when a catheter-based study is negative but clinical suspicion remains high; prefer prolonged monitoring (96 hours) when available.prefer prolonged monitoring (96 hours) if available

Cited in ACG guidance, International Consensus, Lyon Consensus, and RAND panel recommendations.

The Bravo pH Monitoring System should be used within FDA-approved indications and age ranges. Per the device's FDA approval, the Bravo system is not approved for use in individuals under 4 years of age.

Catheter-based ambulatory pH monitoring quantifies esophageal acid exposure but there is no independent reference standard for GERD. Traditional catheter testing has imperfect sensitivity and specificity across populations, and no randomized controlled trials (RCTs) demonstrate that catheter-based pH monitoring improves patient health outcomes. Because clinical validity is not fully established, the test’s role as a standalone method to show improved outcomes is limited.

Longer-duration (prolonged) wireless monitoring typically increases the proportion of tests classified as positive; however, increased positivity alone does not establish superiority. Without an independent reference standard or evidence that management based on longer monitoring improves outcomes, more positive tests cannot be equated with clinical benefit.

Impedance-pH testing combines impedance with pH measurement and can detect nonacid or weakly acidic reflux, increasing diagnostic yield in some studies. Nonetheless, because there is no reference standard for GERD and no RCTs demonstrating improved patient outcomes, the clinical validity and utility of impedance-pH testing remain uncertain in many contexts. Higher positive rates with impedance addition have been reported, but the effect on management or outcomes is not established.

Requests for esophageal pH monitoring that do not meet the policy’s specified medically necessary indications will be considered investigational. In such cases, documentation should show how the requested testing would change management; absent evidence of clinical utility (including RCTs), tests performed outside the listed indications may be denied as investigational.

Routine use of catheter-based pH testing cannot be presumed to improve outcomes. No RCTs were identified assessing clinical utility of catheter-based monitoring, and lack of a reference standard prevents construction of a chain of evidence linking test results to better patient health outcomes. Therefore routine or indiscriminate use of catheter pH testing expecting demonstrated outcome benefit is not supported.

Wireless pH monitoring and impedance-pH testing offer longer recording and increased detection of reflux events, but no randomized controlled trials demonstrate that routine use of these modalities improves clinical outcomes. Because clinical validity for these techniques has not been definitively established, routine use cannot be judged medically necessary solely on improved detection or patient tolerance.

Impedance-pH testing should generally be avoided when the result is unlikely to change management. Given the current evidence gaps and lack of demonstrated clinical utility in some populations, performing impedance-pH testing in situations where it will not inform treatment decisions may be inappropriate and could be considered not medically necessary.

Procedure and Diagnostic Coding

Codes referenced in policymixed

No codes listed

CPT CodesCPT

91034	Esophagus, gastroesophageal reflux test; with nasal catheter pH electrode(s) placement, recording, analysis, and interpretation.
91035	Esophagus, gastroesophageal reflux test; with mucosal attached telemetry pH electrode placement, recording, analysis, and interpretation.
91037	Esophageal function test, gastroesophageal reflux test with nasal catheter intraluminal impedance electrode(s) placement, recording, analysis, and interpretation
91038	Esophageal function test, gastroesophageal reflux test with nasal catheter intraluminal impedance electrode(s) placement, recording, analysis, and interpretation; prolonged (greater than 1 hour, up to 24 hours).

Prolonged wireless pH monitoring diagnostic thresholds

Diagnostic threshold (prolonged wireless monitoring)>6% acid exposure time on 2 or more days is diagnostic for GERD (prolonged wireless monitoring off antisecretory therapy).

Severe acid burden>10% acid exposure time across 2 or more days indicates severe acid burden and may justify escalating anti-reflux treatment.

Non-supportive for PPI therapyAn acid exposure time <4% on all days of monitoring does not support initiation or escalation of PPI therapy.

Refractory on-therapy thresholds

On-therapy acid exposure threshold>4% acid exposure time while on optimal antisecretory (PPI) therapy suggests refractory GERD and supports escalation of anti-reflux treatment.

Reflux episode frequency>80 reflux episodes per day while on therapy is part of the refractory GERD definition.

Combined criteriaBoth elevated acid exposure (>4%) and high reflux episode count (>80/day) on optimal therapy are used to define refractory GERD on therapy per consensus guidance.

Provider Requirements, Prior Authorization, and Documentation

Billing Rule

CPT coding for procedures

Report services with the appropriate CPT/HCPCS/revenue/ICD codes. Use CPT codes 91034 (catheter pH monitoring), 91035 (mucosal-attached telemetry/wireless pH), 91037 (catheter-based impedance-pH), and 91038 (prolonged impedance-pH monitoring up to 24 hours) as applicable. Include place of service and type of service (outpatient/physician office, medical).

Affected CPTs: 91034, 91035, 91037, 91038
Place of service: Outpatient/Physician's Office
Type of service: Medical

Denial Risk

Insufficient evidence for clinical utility

Many studies of impedance-pH and prolonged/wireless pH monitoring lack randomized controlled trials demonstrating improved patient health outcomes. Because clinical utility has not been established through direct evidence or a complete chain of evidence, requests for impedance-pH testing or extended/wireless testing that do not meet medical necessity criteria may be denied as investigational.

No RCTs identified demonstrating clinical utility
Chain of evidence for improved outcomes is weak

Documentation Required

Study selection reporting requirements

Included diagnostic studies should clearly describe the marketed version of the technology evaluated, the reference standard used, patient/sample clinical characteristics, and patient/sample selection criteria. Reports lacking these elements limit assessment of test validity.

Describe marketed device/version and algorithms
Specify suitable reference standard
Report patient characteristics and selection criteria

Denial Risk

Utility not established

Overall utility of impedance-pH testing (and some prolonged/wireless approaches) is not established because there is no accepted reference standard for GERD and no direct evidence showing that test-guided management improves patient outcomes. Positive test yield alone does not confirm clinical benefit and may reduce specificity.

Higher diagnostic yield does not necessarily translate to improved outcomes
Lack of reference standard limits determination of diagnostic accuracy

Denial Risk

Coding-driven denial risk

Coding errors or incomplete reporting of CPT/HCPCS/revenue/ICD codes and lack of supporting documentation (clinical indication, prior evaluation, PPI status, duration of monitoring) increase risk of claim denial. Ensure submitted claims match the service performed and include documentation supporting medical necessity.

Use correct CPT (91034, 91035, 91037, 91038)
Include relevant ICD diagnosis codes supporting indication
Attach supporting clinical documentation to the claim

Documentation Required

Device FDA indication and coding

Use esophageal pH monitoring systems according to FDA-approved indications and labeled age ranges (for example, the Bravo system is not FDA-approved for use in individuals under 4 years of age). Select devices and use duration consistent with device labeling and regulatory approval.

Adhere to FDA-approved indications and age ranges
Bravo pH Monitoring System: not FDA-approved for individuals <4 years

Documentation Required

Study-quality documentation expectations

When submitting studies or supporting clinical documentation, report study quality elements: marketed technology version, reference standard, patient/sample characteristics, and selection criteria. High-quality reporting enables assessment of clinical validity.

Document device/version and any algorithms
Describe reference standard used
Provide patient inclusion/exclusion criteria and demographics

Documentation Required

Document prior evaluation and PPI status

Document prior evaluation thoroughly: results of endoscopy (if performed), prior pH or impedance testing, and detailed PPI therapy status (on vs off therapy, dose, duration, and timing relative to testing). For prolonged/wireless testing, document rationale (eg, negative 24-hour catheter test but persistent symptoms) and prior trial of medical therapy.

Endoscopy findings (dates and results)
Prior pH/impedance testing and results
PPI status: on/off, dose, duration, and timing relative to test

Documentation Required

Required coding documentation

Include CPT codes for the specific service performed (91034, 91035, 91037, 91038) and attach supporting documentation that justifies medical necessity (indication, prior therapy, prior test results, device used, monitoring duration).

Report services with appropriate CPTs: 91034, 91035, 91037, 91038
Provide documentation tying the CPT to the medical necessity criteria

Step Therapy

Medical therapy trial prerequisite

Before ordering pH or impedance-pH testing, document that the patient has had an adequate trial of medical therapy when indicated (for example, a trial of a proton pump inhibitor as described in policy guidance: 4 weeks for otolaryngologic symptoms, 1 month for chest pain evaluation, or as per guideline recommendations). Testing after failure of appropriate medical therapy is a common criterion for coverage.

Document trial of PPI or other medical therapy and lack of symptomatic response
Specify duration and dosing of prior therapy

Note

Step-up to prolonged monitoring

If a standard 24-hour catheter-based study is negative but clinical suspicion remains high, consider step-up to prolonged wireless pH monitoring (eg, up to 96 hours) to increase diagnostic yield. Clearly document the rationale for prolonged monitoring and prior negative results.

Prolonged wireless monitoring (eg, 96 hours) may increase diagnostic yield after negative 24-hour testing
Document prior negative catheter study and reasons for repeat/prolonged testing

Note

Consider objective testing before escalation

Guidelines and consensus statements favor obtaining objective reflux testing rather than indefinite empiric escalation of PPI therapy in many scenarios (eg, isolated extra‑esophageal symptoms or unproven GERD). Document clinical reasoning when choosing testing over prolonged empiric therapy.

Consider upfront objective testing (endoscopy and/or reflux monitoring) in certain patients rather than empiric long-term PPI therapy
Prefer prolonged wireless monitoring off PPI for unproven GERD when appropriate

Background and Scope

Esophageal pH monitoring records lower esophageal pH over ambulatory periods ranging from approximately 24 hours up to 96 hours. Catheter-based systems typically measure for about 24 hours, while wireless (capsule) systems permit prolonged recording (commonly 48–96 hours). These tests aid diagnosis of GERD when endoscopy is nondiagnostic or when symptoms persist despite medical therapy; impedance-pH testing adds impedance sensors to detect liquid or gas reflux events irrespective of pH.

Definitions and Thresholds

Impedance pH monitoring — definition and capability

DefinitionImpedance pH monitoring combines esophageal pH recording with electrical impedance measurements to detect reflux of liquid or gas of any pH.

CapabilityMultiple impedance electrodes along the catheter determine direction of flow and distinguish liquid versus gas reflux events, identifying nonacid or weakly acidic reflux not detected by pH alone.

Use caseUsed to evaluate reflux episodes concurrent with pH changes and to increase detection compared with pH testing alone, including on-therapy assessment.

Clinically Valid — definition

DefinitionClinically valid: a test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Implication for evidenceClinical validity is required to support downstream clinical utility and changes in patient management.

Assessment focusStudies should demonstrate reliable detection performance relative to a condition or outcome of interest to be considered clinically valid.

Impedance-pH testing — combined definition

DefinitionImpedance-pH testing is a technique that combines impedance measurement with pH monitoring to detect both acidic and nonacidic reflux episodes, increasing detection compared with pH alone.

Practical advantageEnables assessment of total reflux burden and characterization of reflux (acidic vs nonacidic), useful for patients on acid-suppression therapy.

LimitationsAlthough it increases positive test yield, evidence is insufficient that impedance-pH testing improves patient outcomes compared with pH testing alone.

Wireless (capsule) pH monitoring — definition and typical durations

DefinitionWireless (capsule) pH monitoring is a catheter-free method using a mucosally attached pH-sensing capsule that transmits data wirelessly to a recorder.

Typical durationsCapsules commonly record pH for up to 48–96 hours (preferred 96 hours for prolonged monitoring off therapy).

Patient experienceStudies show higher patient satisfaction and less discomfort compared with transnasal catheter monitoring.

Diagnostic acid exposure thresholds — consensus thresholds

Consensus diagnostic threshold (prolonged wireless)>6% acid exposure time on two or more days is diagnostic for GERD (prolonged wireless pH monitoring off antisecretory therapy).

Ambulatory pH-impedance (off PPI)Overall total acid exposure time >6% on ambulatory pH-impedance off PPI is diagnostic for GERD per consensus.

Severe burden and non-supportive cut-points>10% across 2+ days indicates severe acid burden; <4% on all days does not support PPI therapy.

Refractory GERD on therapy — definition

Definition of refractory GERD on therapy>4% acid exposure time while on optimal antisecretory therapy plus >80 reflux episodes per day indicates refractory GERD, supporting escalation of anti-reflux treatment.

On-therapy testing rolepH-impedance monitoring while on PPI therapy is recommended to evaluate persistent symptoms and distinguish acid from nonacid reflux.

Consensus basisLyon Consensus and RAND appropriateness statements provide these thresholds as criteria for refractory disease on therapy.

CPT 91034 — definition

91034 — CPT descriptionEsophagus, gastroesophageal reflux test; with nasal catheter pH electrode(s) placement, recording, analysis, and interpretation.

Typical reporting contextUsed to report 24-hour catheter-based esophageal pH monitoring with placement and interpretation services.

Place of serviceOutpatient/physician’s office (per Codes section guidance).

CPT 91035 — definition

91035 — CPT descriptionEsophagus, gastroesophageal reflux test; with mucosal attached telemetry pH electrode placement, recording, analysis, and interpretation.

Typical useUsed to report wireless (mucosal-attached capsule) pH testing with placement, recording, and interpretation services.

Duration implicationReflects telemetry-based (wireless) pH monitoring often performed over prolonged durations (eg, up to 96 hours).

CPT 91037 — definition

91037 — CPT descriptionEsophageal function test, gastroesophageal reflux test with nasal catheter intraluminal impedance electrode(s) placement, recording, analysis, and interpretation.

Typical applicationUsed to report catheter-based intraluminal impedance-pH testing that detects liquid/gas reflux events plus pH changes.

Reporting noteInclude recording, analysis, and interpretation components when billing this code.

CPT 91038 — definition

91038 — CPT descriptionEsophageal function test, gastroesophageal reflux test with nasal catheter intraluminal impedance electrode(s) placement, recording, analysis, and interpretation; prolonged (greater than 1 hour, up to 24 hours).

Duration specificationCode describes prolonged intraluminal impedance-pH monitoring (greater than 1 hour, up to 24 hours).

Use caseApplied when extended catheter-based impedance-pH recording is performed and includes placement and interpretation services.